MEDOVATE ANNOUNCED AS A FINALIST FOR 2022 MED-TECH INNOVATION AWARDS

9th May 2022

Back to News & Events

Medovate – a manufacturer of innovative medical technologies created from within the NHS – is delighted to be announced as a finalist for the 2022 Med-Tech Innovation Awards.

The Cambridge-based medical device development company’s revolutionary device SAFIRA® (SAFer Injection for Regional Anaesthesia) has been shortlisted for this year’s ‘Design Award’, joining 10 other finalists.

The award celebrates significant achievements in product design and engineering of medical device innovations that improve the quality of healthcare delivery and meet a clinical need.

Speaking about the nomination, Managing Director Stuart Thomson said: “We are delighted to be shortlisted for this year’s prestigious Med-Tech Innovation Awards. Our company has achieved a great deal in its first few years, and this is further recognition of our unique approach collaborating with the NHS to develop high-value innovations that can significantly impact patient care and safety. SAFIRA® is a fantastic example of this and provides an intuitive to use technology which fits into existing protocols, reduces the risk of nerve injury and improves patient safety at an acceptable cost.”

Medovate’s SAFIRA® system is an innovative technology which is revolutionising the regional anaesthesia process. The NHS invented solution was developed by Medovate in collaboration with anaesthetists at The Queen Elizabeth Hospital in King’s Lynn.

The award-winning device gives anaesthetists full control of injection, as well as enhancing confidence through a built-in safety mechanism to automatically limit injection pressure to less than 20psi, thus helping to reduce the risk of nerve injury in patients.

The system has been designed to complement other patient safety initiatives with an NRFit® option, while the design and launch of a palm operator controller further provides clinicians with versatility and choice in how they use the system.

Over 20 million regional anaesthetic nerve blocks are performed each year throughout the EU and US. As the use of regional anaesthesia continues to grow globally, the SAFIRA® system provides a unique offering to anaesthetists and their patients and has the potential to make a significant impact on improving patient safety globally.

A winner of the HSJ Patient Safety Innovation of the Year 2021, SAFIRA® has been shortlisted for this year’s Med-Tech Innovation Awards due to its unique benefits to patient safety.

The winners will be announced on 8th June at the Hilton Metropole in Birmingham at the Medilink UK Healthcare Business Awards in association with Med-Tech Innovation.

Details of all the shortlisted finalists can be found here: https://www.med-technews.com/Medtech-expo-and-events/med-tech-innovation-expo-news/two-new-categories-and-35-finalists-for-2022-med-tech-innova/

 

Share this page:

Back to News & Events

FROM CONCEPT TO PRODUCT

Start your journey today

We're experienced in commercialising new medical devices with clinical creators working in the NHS and beyond - call us today for a confidential, no obligation conversation

General Enquiry Form

Complete the short form below with details of your general question or request for information. Fields marked with * are mandatory.

We take your privacy seriously. The information above is required to help us ensure our content is suitable for your needs. “We”, includes Medovate Limited “Medovate”. By clicking submit you confirm that you have read and understood the Medovate Terms of Use and Cookies & Privacy Policy, agree to your data being processed in that way and consent to your details being shared with the relevant Medovate product­ distributor for your country / state so they may contact you in relation to Medovate products.

Newsletter Sign Up

We take your privacy seriously. The information above is required to help us ensure our content is suitable for your needs. “We”, includes Medovate Limited “Medovate”. By clicking submit you confirm that you have read and understood the Medovate Terms of Use and Cookies & Privacy Policy, agree to your data being processed in that way.